NCT00334750 - Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada | Biotech Hunter

Enrollment

410

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

April 30, 2009

Conditions

Glaucoma, Open-AngleOcular Hypertension

Interventions

OTHER

There is no intervention in this study.

This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.

Trial Locations (21)

T3E 7M8

Pfizer Investigational Site, Calgary

T5H 0X5

Pfizer Investigational Site, Edmonton

T5H 3V9

Pfizer Investigational Site, Edmonton

V9R 5B6

Pfizer Investigational Site, Nanaimo

V6K 1V7

Pfizer Investigational Site, Vancouver

V2G 1H1

Pfizer Investigational Site, Williams Lake

R3C 0N2

Pfizer Investigational Site, Winnipeg

B1P 1P2

Pfizer Investigational Site, Sydney

L6V 1B4

Pfizer Investigational Site, Brampton

L8M 1L6

Pfizer Investigational Site, Hamilton

N6A 4V2

Pfizer Investigational Site, London

L5L 1W8

Pfizer Investigational Site, Mississauga

L6H 3P1

Pfizer Investigational Site, Oakville

L6L 5G8

Pfizer Investigational Site, Oakville

M4N 3M5

Pfizer Investigational Site, Toronto

M5M 1B2

Pfizer Investigational Site, Toronto

M5T 2S8

Pfizer Investigational Site, Toronto

H1T 2M4

Pfizer Investigational Site, Montreal

H1V 1G5

Pfizer Investigational Site, Montreal

J1K 1EB

Pfizer Investigational Site, Sherbrooke

S7K 3H3

Pfizer Investigational Site, Saskatoon

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY